There is no information in the provided sources to determine whether the patient required hospitalization due to Cosentyx. However, the sources do provide information on the safety and efficacy of Cosentyx.

Cosentyx (secukinumab) is a biologic drug used to treat certain autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. According to a study published in the Journal of Drugs in Dermatology, Cosentyx has been shown to be safe and effective in treating psoriasis, with a low incidence of adverse events [2]. The most common side effects reported in clinical trials were upper respiratory tract infections, injection site reactions, and diarrhea [2].

The FDA has approved Cosentyx for use in adults with moderate to severe plaque psoriasis, active psoriatic arthritis, and active ankylosing spondylitis [3]. However, the FDA has also issued warnings about the risk of infections associated with the use of Cosentyx, and recommends that patients be monitored for signs of infection during treatment [3].

In conclusion, while the sources do not provide information on whether the patient required hospitalization due to Cosentyx, they do provide information on the safety and efficacy of the drug in treating autoimmune diseases. Patients taking Cosentyx should be aware of the potential risks and side effects associated with the drug, and should be monitored closely by their healthcare provider.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361149/
[3] https://www.fda.gov/media/156152/download